PamelaUryFredaMD

Endocrinology • New York, NY

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Associate Professor, Medicine, Columbia University College of Phys & Surg

Join to view full profile

Dr. Freda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Freda's full profile

Already have an account?

Office
180 Fort Washington Ave
New York, NY 10032
Phone+1 212-305-6238

Education & Training

New York Presbyterian Hospital (Columbia Campus)Fellowship, Endocrinology, Diabetes, and Metabolism, 1991 - 1994
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 1988 - 1991
Columbia University Vagelos College of Physicians and SurgeonsClass of 1988

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2022 - 2025
NY State Medical License 1989 - 2025
CT State Medical License 2022 - 2024
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Measurement of Outcome of Surgical Treatment in Patients With Acromegaly Start of enrollment: 1999 Sep 01
Unknown status
Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas Start of enrollment: 2008 Mar 01
Terminated
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors Start of enrollment: 2008 Jan 01
Terminated
Not Applicable
Effects of Sandostatin LAR® in Acromegaly Start of enrollment: 2006 Aug 01
Unknown status
Phase 4
Prospective Study of Clinically Nonfunctioning Pituitary Adenomas Start of enrollment: 2010 Nov 01
Recruiting
A Prospective Study of Outcome After Therapy for Acromegaly Start of enrollment: 2003 Sep 01
Active, not recruiting
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
Approved for marketing
Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Start of enrollment: 2014 May 23
Completed
Phase 4
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Start of enrollment: 2014 Oct 06
Completed
Phase 3
Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Start of enrollment: 2017 Jul 10
Terminated
Phase 2
Treatment Patterns and Treatment Outcomes for Acromegaly Start of enrollment: 2016 Dec 01
Active, not recruiting
Adipose Tissue and Serum Inflammation in GH Deficiency Start of enrollment: 2019 May 19
Recruiting
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly Start of enrollment: 2019 Aug 19
Completed
Phase 3
Body Composition and Adipose Tissue in HIV Start of enrollment: 2018 Feb 07
Recruiting
Phase 4
Roles: Contact
Effects of GH and Lirglutide on AgRP Start of enrollment: 2023 May 01
Recruiting
Phase 4
Roles: Contact, Principal Investigator
The AgRP and GH/IGF-1 Axis in Children Start of enrollment: 2024 Jun 10
Not yet recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

328 citations
Pituitary incidentaloma: an endocrine society clinical practice guideline.
Pamela U. Freda, Albert Beckers, Laurence Katznelson, Mark E. Molitch, Victor M. Montori
The Journal of Clinical Endocrinology and Metabolism. 2011-04-01
143 citations
A Pituitary Society update to acromegaly management guidelines
Maria Fleseriu, Beverly M. K. Biller, Pamela U. Freda, Mônica R. Gadelha, Andrea Giustina
Pituitary. 2021-02-01
45 citations
Postoperative assessment of the patient after transsphenoidal pituitary surgery
John C. Ausiello, Jeffrey N. Bruce, Pamela U. Freda
Pituitary. 2008-03-05

Lectures

Neuroendocrinology and Pituitary
ENDO 2019 - New Orleans, LA - 3/23/2019

Press Mentions

Longer Exposure to Excess IGF-I Levels May Raise Cancer Risk for Adults with AcromegalyAugust 19th, 2024
Pituitary Incidentalomas: New Guideline Recommends That Patients Undergo Complete History and Physical ExaminationApril 7th, 2011

Grant Support

Prospective Study Of Clinically Non-Functioning Pituitary AdenomasNational Institute Of Neurological Disorders And Stroke2010–2011
New Approaches To The Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
New Approaches To The Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
New Approaches To Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases2005–2009
New Approaches To Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2008
Nalmefene TestingNational Center For Research Resources2004
New Approaches To Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2003
New Approaches To Evaluation And Treatment Of AcromegalyNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2003
SEN 3614:Random ,Dbl Blind,Placebo Cont Study Of B2036 PEG In Treat ANational Center For Research Resources1999–2002
Outcome Of Surgical Therapy For AcromegalyNational Center For Research Resources1997–2002
Gonadotropin Response To ACTHNational Center For Research Resources1999–2000
Pilot Study Of Cabergoline Treatment For AcromegalyNational Center For Research Resources1998–2000